SAMEA14083393 ERS11686527 Akkermansia muciniphila This sample represents a Third Party Annotation (TPA) Metagenome-Assembled Genome (MAG) assembled from the metagenomic run ERR1190926 of study ERP013563. EBI Generic Generic.1.0 ERC000047 2023-01-03 2023-01-03 SAMEA14083393 EBI European Bioinformatics Institute 2023-01-03T00:33:27Z 2023-01-03T00:33:27Z public ERR1190926_bin.130_CONCOCT_v1.1_MAG Many fragments with little to no review of assembly other than reporting of standard assembly statistics spades_v3.11.1 Default CONCOCT v1.1 EMG broker account, EMBL-EBI 2014-01-01 97.96 CheckM 0.0 Host-associated Human Digestive system China 55.676098 12.568337 metagenome-assembled genome human gut metagenome human gut metagenome Dysbosis of intestinal microbiota could contribute to the pathogenesis of Type 2 Diabetes. It is yet to be known whether intestinal flora could be related to differential responds to antidiabetic therapies. This study, herein for the first time, metagenomic sequenced fecal samples from a randomized clinical trial on new onset untreated Type 2 Diabetes patients applied two treatment arms, Acarbose and Glipizide (Sulfonylurea) and analyzed the differential responses of intestinal flora in different groups. Results showed substantial impact of Acarbose on gut microbiota community but minor of Glipizide. Enterotypes with similar baseline clinical characteristics, had significant different pharmacologic respond to Acarbose on insulin resistance, gut hormones, bile acids and cardiovascular risks, indicating that different pattern of intestinal microbiota component could determine different responses of Type 2 Diabetes to antidiabetic pharmacological therapies. SAMEA3708852 ERR1190926_bin.130_CONCOCT_v1.1_MAG Akkermansia muciniphila Illumina HiSeq 2500 multi-marker approach